Introduction
============

Cervical cancer worldwide has the third leading incidence of all malignancies in women, ranking in the top five diseases causing mortality\[[@B4],[@B10],[@B14],[@B16]\]. The incidence in Europe is 13.4 per 100,000 women and in our country 34.9 cases per 100,000 women,\[[@B5],[@B6],[@B38], [@B39], [@B40]\]. Romania has the highest incidence of cancer mortality in the age group 15-44 years in Europe.\[[@B34],[@B36],[@B37]\]

It is well known that cervical ectropion is a cervical lesion with oncogenic risk, but the studies are still inconsistent on solving this type of injuries \[[@B21],[@B24],[@B26],[@B29],[@B31]\]. What is more, nowadays the 14-37% reported incidence for cervical ectropion is increasing.\[[@B23],[@B25],[@B27],[@B30]\] Also, aditional diagnosis of Chlamydia, Mycoplasma, Ureaplasma, HPV, HvS2, places the patient into a group of greater oncogenic risk.\[[@B1], [@B2], [@B3],[@B8],[@B13]\]

Antimicrobial-- hormonal combined therapy is an important tool to manage such cases with potential dysplastic oncogenic impact\[[@B7],[@B9],[@B11],[@B12]\]. Progesterone administered intermittently during ovulatory to luteal phase, between days 10-14, with varying doses depending on serologically proven deficiency in patients with premenstrual syndrome presenting cervical lesions of the cervix, leads to the induction of transformation zone restriction with re-epithelization in the squamous epithelium \[[@B15],[@B30],[@B32],[@B36]\]. However, there is scarce data in the literature regarding the cervical ultrasound imaging using volumetric, linear and Doppler ultrasound (measurement of uterine artery resistance indices) and prompted our study into this segment.\[[@B17],[@B18],[@B22],[@B33]\]

Aim
===

We chose to conduct a sonographic study in patients diagnosed and treated for congenital ectropion to investigate the importance of various ultrasound prognosis features, in order to create an effective algorithm for treatment monitoring.

Methods
=======

During the study period, patients were admitted into the study group after signing an informed consent. Then they were subject to an investigation protocol aimed to investigate the prognosis potential of several measurable cervical parameters that can be used for monitoring the cervical ectropion treatment ([1](#F1){ref-type="fig"}).

Inclusion criteria was the presence of ectropion and the selection was based on clinical examination performed during routine consultations in specialized clinics, later confirmed by colposcopic evaluation of cervix.

Demographic data recorded in the patients were: age, origin, characteristics of the menstrual cycle, comorbidities, history of personal or familial cervical pathology.

![Protocol diagram](CHSJ-42-02-11-fig1){#F1}

Evaluation protocol for the studied patients included:

A. Clinical general and local evaluation, completed with colposcopy+/- colposcopic guided biopsy.

B.Serology Assay: day 21 progesteronemy (to determine the hormonal context for ectropion evolution); IgM and IgG HVS2; Atg Chlamydia, Mycoplasma and Ureaplasma, HPV DNA typing; vaginal bacteriology.

C. Transvaginal ultrasound serial evaluation at the 7th, 14th, 21st day concerning: uterine and cervical volumetric calculations and velocimetric measurements of uterine arteries flows. We used Voluson E6 ultrasound equipment from General Electrics.

After determining the ectropion diagnosis and area, the serologic progesterone level and the infectious context, progestative treatment was prescribed hormone, and antiinfectious specific treatment when needed, with reassessment after 3 months.

Antibiotic protocol was standard with tetracycline, macrolides and quinolones whose efficiency was investigated at 3 months reevaluation. Antiviral therapy was initiated using Isoprinosine for HPV and valacyclovir for HVS2.

Statistical analysis of data

For data processing we used IBM SPSS Statistics 20.0 software (IBM Corporation, Armonk, NY, USA).

For data normality tests we used Shapiro-Wilks and Kolmogorov-Smirnov.

To study the evolution of volumes, IR and ectropion level under therapy, in case of normal distribution of data we used Paired -- samples T test and Wilcoxon Signed Rank validity test for data that did not have normal distribution.

Patients were studied as a global group, but also as separate subgroups divided according to different variables.

For data analysis we used frequency tables which included two columns: one for distinct values of the variable analyzed, and the other for frequencies of those values.

Descriptive statistics (mean and standard deviation or median with minimum and maximum value) was used for the presentation of the basic characteristics.

Results
=======

The prospective study included 45 patients between 2013-2014.

###### 

Associated infections in the studied group

  --------------- ----------------- ------
  Infection       Number of cases   \%
  Atg Chlamydia   4                 8.9
  Mycoplasma      4                 8.9
  Ureaplasma      12                26.7
  --------------- ----------------- ------

Out of 45 patients, we identified Chlamydia infection in 4 patients, mycoplasma in 12 patients and ureaplsma in 4 patients ([1](#T1){ref-type="table"}).

Hormonal profile of patients with ectropion

Patients were divided into 2 subgroups: 28 presented serum progesterone levels below the reference range or borderline reduced and 17 patients had serological values of progesterone in the normal reference interval.

Colposcopic guided biopsy results

Histopathological study with HE staining, of the 45 cases revealed a number of changes in the area of ectropion. Please note that in some cases, were identified two or more microscopic changes described below. Microscopic changes observed with usual staining in ectropion areas were grouped as follows ([2](#T2){ref-type="table"}):

###### 

Histopatological findings with HE stain

  ------------------------------------------- ---- ------
  Histopatological findings                   N    \%
  Nonspecific inflamatory tissue              16   35.6
  Koylocites                                  16   35.6
  Metaplasia imature                          5    11.1
  Metaplasia mature                           15   33.3
  Displasya medium                            2    4.4
  Displasya mild                              9    20.0
  Acanthosis                                  7    15.6
  Acanthosis, papillomatosis                  4    8.9
  Acanthosis, papillomatosis, parakeratosis   2    4.4
  Parakeratosis                               1    2.2
  Parakeratosis, acanthosis                   4    8.9
  Intraepithelial vesicle                     1    2.2
  ------------------------------------------- ---- ------

Systemic and local hormonal treatment

The 50 patients were prescribed with different treatment schedules based on particular benefit for each case. 5 patients were excluded from statistical analysis because they did not accept any hormonal treatment.

In the studied cases semi-synthetic progestogen therapy was indicated in the luteal phase (nomegestrol acetate 5 mg/day or 10-20 mg dydrogesterone/day) or derivatives of natural micronized progesterone.

Colposcopic evaluation after treatment

We noted a moderate reduction of the ectropion area in 19 cases (aproximately 42 % ) and a marked reduction in 26 cases (58%).

![A: Ciliar tubal metaplasia and plasmocytes cervicitis associated with ectropion and chronic inflammatory infiltrate in the corium prone to formation of lymphoid follicles, col. HE. B: Micropolipos aspect of ectropion area, vascular ectasia, inflammatory infiltrate and LSIL (CIN I) on squamous metaplasia, col.HE. C: HSIL on squamous metaplasia area, col. HE](CHSJ-42-02-11-fig2){#F2}

![Ectropion severity regression](CHSJ-42-02-11-fig3){#F3}

![Colposcopy in HPV negative patient with ectropion (marked with arrow), before (A, C) and after treatment (B, D). A: acetic acid staining of the cervix, before treatment. B: ectropion remission after six months, acid acetic aplication. C: ectropion extent evaluated using Lugol's stain. D: ectropion remission after six months, same patient, iodine staining](CHSJ-42-02-11-fig4){#F4}

Ultrasonographicstudy results
=============================

Cervical volumetry interrelated with menstrual cycle phases ([5](#F5){ref-type="fig"})

![3D ultrasound of the cervix. Patients with Chlamydia, on 7th day of MC before treatment (volume 19,418 cm3) and 7th day of MC after treatment (volume 11 640cm3)](CHSJ-42-02-11-fig5){#F5}

No other statistically significant differences were found between the size of the cervix before or after treatment, than differences in absolute value. Cervical volumes were reduced in certain evaluations (for example the 7th and the 14th day) in the presence of bacterial coinfections ([3](#T3){ref-type="table"}).

###### 

Cervical volumes in the presence of coinfections ( Data are expressed as average +/-SD; P \< 0.05 -- statistically significant -- T pair test)\*. CB: cervical biopsy

  ------------------------ -------------------------------------- ------------------ ----------------- --------- ------- -------- ---------
                                                                  Before treatment   After treatment                              
                                                                  Average            SD                Average   SD      t        p value
  Cervical volume day 7                                                                                                            
                           Chlamydia +                            20.058             6.216             22.747    5.870   -7.040   0.006
                           Ureaplasma +                           24.156             7.350             21.161    5.582   3.165    0.009
  Cervical volume day 14                                                                                                           
                           Chlamydia -                            24.604             7.230             23.037    5.202   2.097    0.042
                           Ureaplasma +                           26.693             7.217             23.085    5.770   2.504    0.029
                           HPV HR                                 28.566             8.542             23.705    6.944   2.686    0.036
                           Nonspecific inflamatory tissue(CB)\*   25.260             7.278             22.663    5.636   2.198    0.044
  ------------------------ -------------------------------------- ------------------ ----------------- --------- ------- -------- ---------

After hormonall treatment, followed by the reduction of the ectropion, there were no statistically significant differences in the volumetric measurements of the cervix.([4](#T4){ref-type="table"}).

###### 

Cervical volume after progestative treatment ( Data are expressed as average +/-SD; P \< 0.05 -- statistically significant -- T pair test)

  ------------------------ ------------------ ----------------- -------- -------
                           Before treatment   After treatment             
                           Average+/-SD       Average+/-SD      t        p
  Cervical volume day 7    22.21 ± 7.06       22.12 ± 6.33      0.143    0.887
  Cervical volume day 14   24.12 ± 7.31       22.83 ± 5.1       1.826    0.075
  Cervical volume day 21   23.23 ± 6.67       23.33 ± 5.73      -0.164   0.871
  ------------------------ ------------------ ----------------- -------- -------

Imagistic reduction of the cervix volume after treatment was statistically significant for day 7 in patients with positive Clamydia and Ureaplasma.

Cervical volume reduction measured on day 14 of the menstrual cycle, was statistically significant for patients HPV HR+, correlated with low progesterone serologic values. Also, in the same high statistical significance interval, entered patients who experienced frequent menstrual cycles (days 21-25) and in a lesser extent, patients with non specific inflammatory histopathological result.

Evaluation of uterine artery velocimetry
========================================

###### 

Variation in resistance indices after treatment for uterine arteries for the entire lot of patients. Data are expressed as average +/-SD in case of normal distribution, or as median in case of abnormal distribution. P \< 0.05 -- statistically significant ( T pair test for normal distribution data and Wilcoxon Signed Rank test for abnormal distribution data)

  ----------------- --------------- ---------------- ---------------- ------ ---- ------
                    Right UAday 7   Right UAday 14   Right UAday 21               
  \% RI reduction   N               \%               N                \%     N    \%
  \>(-50%)          0               0                0                0      1    2.2
  (-50%)-(-25%)     0               0                0                0      0    0
  (-25%)--0         29              64.4             30               66.7   17   37.8
  0-25%             16              35.6             15               33.3   27   60.0
  25%-50%           0               0                0                0      0    0
  \>50%             0               0                0                0      0    0
                    Left UA day 7   Left UA day 14   Left UA day21                
  \% RI reduction   N               \%               N                \%     N    \%
  \>(-50%)          0               0                0                0      0    0
  (-50%) - (-25%)   0               0                0                0      0    0
  (-25%) -- 0       27              60.0             15               33.3   30   66.7
  0-25%             18              40.0             30               66.7   15   33.3
  25%-50%           0               0                0                0      0    0
  \>50%             0               0                0                0      0    0
  ----------------- --------------- ---------------- ---------------- ------ ---- ------

Discussion
==========

This study confirms previous research that induction of luteal phase progestogen hormone treatment induces the decrease of ectropion extension, that further may lead to the decrease of the transformation zone and spontaneous negativation of viral infection sand involution of cervical lesions.

No statistically significant differences were noted in th eoverall cervical volumetric measurement after treatment was administred. However, measurements taken on day 7 and day 21 in patients infected with chlamydia, showed a significant decrease in the cervical volume after treatment and especially after treatment with cephalosporin, but the result should be validated in a larger study. This could suggest a reduction in cervical volume by decreasing inflammation, since hormonal therapy was not significantly involved as an independent variable. The variation of the cervical volume was significant but less notable in the cases of ureaplasma and mycoplasma infections.

Evaluation of pulsed Doppler velocimetric indices of uterine arteries flows showed absolute variations but the vast majority were minor, up to 25% from the initial findings. We could not identify a constant positive or negative trend, in any of the uterine arteries, during the menstrual cycle, and also the indices varied widely as amplitude. Note that these indexes have suffered the most significant changes in the periovulatory phase at the left uterine artery towards lower values, but later in the day 21, in the end of treatment, the respective indices were increased compared to previous values. Moreover, this trend has not been followed by the measurements in the contralateral uterine artery. Since changes were inconstant and minor, we conclude that uterine vasculature was not influenced by the treatment or remission of the cervical ectropion . An issue that requires further investigation with possible prognostic implication is that the changes in resistance uterine arteries index was higher in patients without Chlamydia infection and positive for HPV-HR infection and patients with low progesteronemy. It might be true the hypotesys that progesterone therapy is more effective if the ectropion is \"clean\" bacteriological and viral, but this assumption requires confirmation by further research with similar therapeutic protocol. Based on the data obtained in our study, we conclude that ultrasound monitoring of ectropion treatment do not provide reliable prognosis data regarding the evolution of cervical lesion.
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